Comparison of pharmacodynamic properties of three different aspirin formualtions in the patients with stable coronary disease

Ana Antić; Zoran Stanojković; Miodrag Vučić; Milan Lazarević; Nebojša Vacić

doi:10.2298/VSP180110034A

Ana Antić Blood Transfusion Institute, Niš, Serbia
Zoran Stanojković Blood Transfusion Institute, Niš, Serbia
Miodrag Vučić Clinical Center Niš, Clinic for Hematology, Niš, Serbia
Milan Lazarević Clinical Center Niš, Clinic for Cardiovascular and Transplantation Surgery, Niš, Serbia
Nebojša Vacić Clinical Center Niš, Clinic for Hematology, Niš, Serbia

DOI: https://doi.org/10.2298/VSP180110034A

Keywords: platelet aggregation;, aggregation inhibitors;, aspirin;, clopidogrel;, acute coronary syndrome;, treatment outcome.

Abstract

Background/Aim. The platelet aggregation, as a laboratory test for assessment of platelet function, is very efficient for optimal antiplatelet treatment and also to identify individuals who have suboptimal response to antiplatelet drugs, such as aspirin and clopidogrel. The aim of this study was to determine the level of inhibition of platelet aggregation using impedance aggregometry in the patients receiving different preparations of acetylsalicylic acid (ASA) in a dose of 100 mg per day. Methods. The examination included 215 patients (110 men and 105 women), treated with one of three different ASA preparations after acute myocardial infarction, as a single therapy or with clopidogrel. Among them, 89 patients were on Aspirin protect^® (Bayer, Germany) – Group 1 and 66 patients were on Cardiopirin^® (GL Pharma GMBH, Austria) – Group 2, while 60 patients were taking Andol^® (Pliva, Croatia) – Group 3. The groups were equal in the presence of factors that can influence platelet aggregation (age, gender, smoking, diabetes, taking other drugs). The platelet function was measured using the impedance aggregometer Multiplate (Multiplate Platelet Function Analyzer, Roche) in the blood samples with heparin for the platelet aggregation activated by the arachidonic acid (ASPI) and by thrombin (TRAP) tests [the area under the aggregation curve (AUC) was used to express the aggregation response over the measured time (AU*min)]. Results. Efficacy of ASA preparations showed statistically significant differences among the three investigated groups (χ_KW²= 46.279; p < 0.001), and it was also observed separately in the patients undergoing single therapy (χ_KW²= 26.344; p < 0.001) and dual therapy (χ_KW²= 23.498; p < 0.001). It was found that the patients who were taking Aspirin protect^® obtained significantly better antiplatelet efficiency compared to the patients receiving Cardiopirin^® (Z = 5.472; p < 0.001) and Andol^® (Z = 5.387; p = 0.022). There is reduced efficiency of all ASA preparations in smokers, while patients receiving Aspirin protect^® were 10.5 times more likely to be responders. Conclusion. Different ASA preparations observed in this study showed different efficiency on the platelet function as measured by the method of impedance aggregometry.

Author Biography

Ana Antić, Blood Transfusion Institute, Niš, Serbia

PhD

References

Reininger AJ. Primary haemostasis and its assessment by labor-atory tests.Hamostaseologie 2006; 26(1): 42–4, 46–7.

Guyer KE. The present state of aspirin and clopidogrel re-sistance. Hämostaseologie 2009; 29(3): 285–90.

Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardi-ovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51(19): 1829–43.

Grove EL. Antiplatelet effect of aspirin in patients with coro-nary artery disease. Dan Med J 2012; 59(9): B4506.

Campbell CL, Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance. J Thromb Haemost 2005; 3(4): 665–9.

Zimmerman N, Hohlfeld T. Clinical implications of aspirin re-sistance. Thromb Haemost 2008; 100(3): 379–90.

Schwartz KA. Aspirin Resistance: A Clinical Review Focused on the Most Common Cause, Noncompliance. Neurohospital-ist 2011; 1(2): 94–103.

Mehta JL, Mohandas B. Aspirin resistance: Fact or fiction? A point of view. World J Cardiol 2010; 2(9): 280–8.

Patrono C. The Multifaceted Clinical Readouts of Platelet In-hibition by Low-Dose Aspirin. J Am Coll Cardiol 2015; 66(1): 74–85.

Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivi-ty and antiplatelet therapy resistance. Semin Thromb Hemost 2012; 38(2): 200–12.

Dawson J, Quinn T, Rafferty M, Higgins P, Ray G, Lees KR, et al. Aspirin resistance and compliance with therapy. Cardiovasc Ther 2011; 29(5): 301–7.

Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin. Am Heart J 2004; 147(2): 293–300.

Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, et al. Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs. Circulation 2003; 108(10): 1191–5.

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013; 127(3): 377–85.

Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharma-col Ther 2014; 141(1): 69–78.

Harrison P, Frelinger AL, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120(3): 323–36.

Alberts MJ. Platelet function testing for aspirin resistance is reasonable to do: yes. Stroke 2010; 41(10): 2400–1.

Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance.”. J Am Coll Cardiol 2009; 53(8): 667–77.

Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009; 131(6): 834–42.

Schror K. What is aspirin resistance? Br J Cardiol 2010 17(Suppl 1): S5–S7.

Adamzik M, Görlinger K, Peters J, Hartmann M. Whole blood impedance aggregometry as a biomarker for the diagnosis and prognosis of severe sepsis. Critical Care 2012; 16(5): R204.

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC Scientific Document Group . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the Europe-an Society of Cardiology (ESC). Eur Heart J 2018; 39(2): 119–77.

Goodman SG, Menon V, Cannon CP, Steg G, Ohman E, Harring-ton RA. American College of Chest Physicians. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(6): 708S–75S.

Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Throm-bosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e120S–e151S.

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfa-rin, Aspirin, or Both after Myocardial Infarction. N Engl J Med 2002; 347(13): 969–74.

Buchanan MR, Verma S. Biological basis and clinical implica-tions of acetylsalicylic acid resistance. Can J Cardiol 2006; 22(2): 149–51.

Cheng X, Xie N, Xu H, Chen C, Lian Y. Biochemical aspirin resistance is associated with increased stroke severity and in-farct volumes in ischemic stroke patients. Oncotarget 2017; 8(44): 77086–95.

Liu L, Cao J, Fan L, Hu G, Hu Y, Zhu B, et al. Prevalence and Risk Factors for Aspirin Resistance in Elderly Patients With Type 2 Diabetes. Int J Gerontol 2011; 5(2): 112–6.

Alahmari S, Alayed K, Malik A, Abdel GA, Albanyan A, Al-Shaikh Y. Measurement of platelet function to determine the prevalence of aspirin non-responsiveness among Saudi type II diabetic patients. J Health Spec 2016; 4(1): 31–6.

Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas A. Re-duced platelet response to aspirin in patients with coronary ar-tery disease and type 2 diabetes mellitus. Thromb Res 2010; 126(4): e318–2.

Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011; 57(9): 1069–77.

Škorić B, Miličić D, Lovrić D, Gornik I, Škorić-Narančić K, Sertić J. Initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction is related to platelet response to aspirin. Int J Cardiol 2010; 140(3): 356–8.

Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41(6): 961–5.

Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “re-sistance” and risk of cardiovascular morbidity: systematic re-view and meta-analysis. BMJ 2008; 336(7637): 195–8.

Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis 2012; 2012: 376721.